Actively Recruiting
Resmiterom Efficacy & Safety in Patients With MASH
Led by Nabiqasim Industries (Pvt) Ltd · Updated on 2025-12-03
165
Participants Needed
1
Research Sites
62 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
CONDITIONS
Official Title
Resmiterom Efficacy & Safety in Patients With MASH
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- At least one metabolic comorbidity such as type 2 diabetes, obesity, dyslipidemia, or hypertension
- Clinical diagnosis of MASH using at least one of the following: liver stiffness measurement (LSM) 8.5 kPa, FAST score 0.67, FibroScan CAP 275 dB/m, or FIB-4 > 1.3
You will not qualify if you...
- History of drug addiction or alcoholism
- Cirrhosis or decompensated liver disease
- Chronic viral hepatitis (HBV, HCV)
- Major adverse cardiovascular events including myocardial infarction, stroke, or pulmonary embolism
- Pregnant or lactating women
- Concurrent use of other investigational drugs
- History of other liver diseases (viral, autoimmune, drug-induced, alcoholic)
- Previous use of Resmetirom in the last 6 months
- Significant renal impairment with eGFR < 30
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Liver transplant center, Holy family hospital
Rawalpindi, Punjab Province, Pakistan
Actively Recruiting
Research Team
H
Hussain B Abidi, MBBS, MBA, CRCP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here